119
Participants
Start Date
November 12, 2013
Primary Completion Date
August 21, 2017
Study Completion Date
August 21, 2017
SD-809
SD-809 tablets will be provided in dose strengths of 6, 9 and 12 mg.
Teva Investigational Site 054, Sydney
Teva Investigational Site 002, New York
Teva Investigational Site 342, Patchogue
Teva Investigational Site 037, Albany
Teva Investigational Site 333, Washington D.C.
Teva Investigational Site 028, Baltimore
Teva Investigational Site 119, Durham
Teva Investigational Site 032, Atlanta
Teva Investigational Site 160, Gainesville
Teva Investigational Site 014, Miami
Teva Investigational Site 057, Birmingham
Teva Investigational Site 087, Louisville
Teva Investigational Site 020, Columbus
Teva Investigational Site 089, Cincinnati
Teva Investigational Site 045, Indianapolis
Teva Investigational Site 024, Iowa City
Teva Investigational Site 027, St Louis
Teva Investigational Site 029, Kansas City
Teva Investigational Site 083, Wichita
Teva Investigational Site 298, Fayetteville
Teva Investigational Site 341, Tulsa
Teva Investigational Site 007, Houston
Teva Investigational Site 199, Houston
Teva Investigational Site 052, Englewood
Teva Investigational Site 100, Salt Lake City
Teva Investigational Site 038, Phoenix
Teva Investigational Site 194, Las Vegas
Teva Investigational Site 220, Kirkland
Teva Investigational Site 096, Seattle
Teva Investigational Site 040, Boston
Teva Investigational Site 328, Camden
Teva Investigational Site 026, New Brunswick
Teva Investigational Site 093, Toledo
Teva Investigational Site 031, Nashville
Teva Investigational Site 137, Burlington
Teva Investigational Site 098, Montreal
Teva Investigational Site 231, Ottawa
Teva Investigational Site 300, Toronto
Lead Sponsor
Auspex Pharmaceuticals, Inc.
INDUSTRY